Protalix BioTherapeutics (PLX) Net Income towards Common Stockholders Growth (5y) (2015 - 2026)
Protalix BioTherapeutics (PLX) Net Income towards Common Stockholders Growth (5y) (2015 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Protalix BioTherapeutics | 189.97 Mn | 149.31 Mn | 12.13 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 18.46% |
| Mar 31, 2026 | 38.72% |
| Dec 31, 2025 | -49.12% |
| Sep 30, 2025 | 20.40% |
| Jun 30, 2025 | 15.93% |
| Mar 31, 2025 | -34.93% |
| Dec 31, 2024 | 149.84% |
| Sep 30, 2024 | 24.29% |
| Jun 30, 2024 | 22.23% |
| Mar 31, 2024 | 9.22% |
| Dec 31, 2023 | -17.60% |
| Sep 30, 2023 | 19.71% |
| Jun 30, 2023 | 31.28% |
| Mar 31, 2023 | 15.74% |
| Dec 31, 2022 | 10.62% |
| Jun 30, 2021 | -149.75% |
| Mar 31, 2021 | -141.06% |
| Dec 31, 2020 | -61.75% |
| Sep 30, 2020 | -32.44% |
| Jun 30, 2020 | -41.96% |